---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-031477"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:42:21.557328+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix Q2 2024 net loss widens to $5.8M; cash runway extended to Q4 2026

## Summary
- Net loss widened to $5.8M ($1.59/sh) from $3.8M ($1.04) a year ago; revenue fell to $1.6M from $1.8M.
- Cash and equivalents $12.4M plus $1.4M restricted cash released; projected cash runway into Q4 2026 after MannKind transactions.
- Recorded $2.6M loss on disposal group for assets transferred to MannKind in connection with iSPERSE technology validation.
- Halted Phase 2b enrollment for PUR1900 with Cipla; wind down by Q3 2024; no further development funding, 2% royalty on future ex-US sales.

## SEC filing metadata
- accession: 0001493152-24-031477
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315224031477/0001493152-24-031477-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315224031477/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-031477
- JSON: https://secwatch.observer/filing/0001493152-24-031477.json
- Plain text: https://secwatch.observer/filing/0001493152-24-031477.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.